The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 mAbs recognizing two different epitopes on the human T-lymphocyte antigen, CD4. The chimerized mAbs are produced at levels corresponding to those of the original hybridoma cell lines. With respect to activation of human complement, the individual Abs are negative; however, when used in combination, complement activation was performed. When applied in combination, they were found to modulate the CD4 antigen, whereas the individual mAb do not display this property. Individually they mediate an up to 60% inhibition of the mixed lymphocyte reaction (MLR). However, by combination of an anti-CD4 mAb with one directed against the a-chain of the human IL2 receptor, nearly 100% inhibition of the MLR was achieved, even with reduced dosage of the mAbs. Our data suggest that the combination of an anti-CD4 mAb and an anti-IL2Rcc chain mAb is more effective with respect to immunosuppression than each mAb by itself, indicating that this mAb cocktail could be a new strategy for immunosuppressive therapy.
INTRODUCTION
Antibodies that recognize antigens on the surface of human lymphocytes have been used as immunosuppressive agents for more than 20 years. Since the development of techniques to produce mAb (Kbhler and Milstein, 1975) that recognize a variety of antigens on the lymphocyte surface, mAbs are clinically applied for the diagnosis and ther-apy of an array of human disorders. Possible targets for immune intervention focus on two antigens expressed by T lymphocytes. CD4 is only expressed by a subset of T lymphocytes. This phenotype is usually, but not exclusively, (Kabat et al., 1987) are underlined. The numbers below the sequence indicate aa positions; 1 indicates the first aa of the mature protein; upstream aa represent the signal sequence. The numbers on the left margin specify the nt positions, with nt = 1 corresponding to the A of the ATG start codon. In (a) the J, region of the L chain of mAb M-T15 1 is from Tyr% to Lys"', m (b) the J, region of the H chain is from Asp"* to Ser I*', in (c) the J, region of the L chain of mAb M-T3 10 is from Thr"' to Lys "I, in (d) the J, region of the H chain is from His"' to Ala"'. Methods. RNA was isolated from 1 x 10' hybridoma cells secreting mAbs M-T151 and M-T310 and selected for poly(A)+RNA on oligo(dT) cellulose (Maniatis et al., 1982 (Cobbold et al., 1984; Miller et al., 1985) have led to clinical evaluation of anti-CD4 mAbs in the serotherapy of diseases (Herzog et al., 1987; Reiter et al., 1991; Reinke et al., 1991) . The IL2R is a target of considerable interest, particularly as it is an activation antigen, composed of an inducible a chain (55 kDa) and a p chain (75 kDa), which only appears on the surface of T lymphocytes when they are activated by antigen or mitogen. Successful therapeutical application of an IL2R mAb has been already shown by different groups (Kyle et al., 1989; HervC et al., 1990; Waldmann, 1991a) . Since there are limitations to administering non-human proteins, efforts to engineer new generations of antibodies are underway and are directed towards making the antibodies more human-like, with the aim of lowering the immunogenicity of these proteins in man and optimizing their physiological effector functions and pharmacokinetic characteristics. One approach to decrease mAb immunogenicity (Morrison et al., 1984) is the synthesis of chimeric mAb. After the demonstration that lymphoid cells can express cloned, transfected Ig genes, mouse/human chimeric mAbs were generated with specificities directed towards a wide range of tumour antigens and T-cell surface molecules. The benefits of chimeric mAb for serotherapy in humans are widely accepted.
The aim of this work was to generate chimeric mouse/ human antibodies directed against the T-cell antigen CD4.
Furthermore, the chimeric mAbs M-T310 and M-T151 were analysed alone and in combination with MAK 179, an IL2Rcr chimeric mAb (Kaluza et al., 1991) , with respect to their physiological effector functions. With the aim of possible clinical application, we have evaluated in vitro possible synergistic effects between the two anti-CD4 mAb M-T310 and M-T151, recognizing two different epitopes on the first and second extracellular domains of the T-cell surface glycoprotein CD4 (Peterson and Seed, 1988; Sattentau et al., 1989; Ashkenazi et al., 1990 ) and combinations of the two anti-CD4-specific chimeric mAbs with the IL2Ra-specific chimeric mAb MAK 179.
RESULTS AND DISCUSSION

(a) Cloning and sequence analysis of V region sequences
The functionally rearranged V, and V, regions of mAbs M-T310 and M-T151 have been cloned and subsequently fused to human constant region gene segments encoding the human yl chain (vector pUHWy1) and human IC chain (vector pUHWrc), as described (Weissenhorn et al., 1991) . The nt and the deduced aa sequences of anti-CD4 mAb V, and V, regions are shown in Fig. 1 . Both the V, and V, sequences of anti-CD4 mAbs M-T310 and M-T151 show no significant homology with respect to their nt and aa sequences. The V, region genes can be attributed to two different VH gene families according to previously defined and y transcripts of mAb M-T151: a-f, K transcripts; g-l, y transcripts; a-d, four transfectomas; e, hybridoma; f, Sp2/0, g-j, four transfectomas corresponding to those in lanes a-d; k, hybridoma; I, Sp2/0. Methods. Total RNA was extracted from 1 x 10' cells according to the method described by Auffray and Rougeon (1980) . Ten pg of total RNA was electrophoresed on a 1.2% agarose gel containing 2.2 M formaldehyde and transferred to a nitrocellulose membrane (Amersham, Braunschweig, Germany) by standard procedures (Maniatis et al., 1982) . The blots were hybridized with V-specific probes.
For detection of K mRNA a 274-bp EcoRV-Not1 fragment was used for M-T151; for M-T310 a 248-bp KpnI-Not1 fragment was used as a probe. The y transcripts were detected with the following probes: a 767-bp Sty1 fragment for mAb M-T310 and a 367-bp BarnHI-BglII fragment for M-T151. Radioactive probes were obtained by labelling the fragments with [ c(-3ZP]dCTP using the random primed DNA-labelling kit supplied by Boehringer Mannheim.
Then 2 x lo6 cpm per labelled fragment were used for hybridization, which was performed as described in Maniatis et al. (1982) .
V, gene families. V gene families comprise groups of related V genes that in general share greater than 80% sequence similarity (Brodeur and Riblet, 1984; Winter et al., 1985; Kabat et al., 1987 (Kurosawa and Tonegawa, 1982) , they all show regions of homology flanked by relatively G-rich sequences (N sequences) which have previously been proposed to be inserted during V,-D and D-J, joining events (Alt and Baltimore, 1982) . Similar results were obtained for the VIC sequences. M-T3 10 Vlc is a member of the V1c21 subgroup and Vlc M-T151 of the VlclO subgroup (Kabat et al., 1987; Kofler et al., 1989; Strohal et al., 1989) . VK M-T310 is rearranged to Jl and VK. M-T151, to 52. This diversity in sequence correlates with their different CD4 antigen binding pattern. Both mAbs recognize different epitopes on the CD4 molecule as indicated by cross-blocking experiments (data not shown), and they map to different antigenic regions, as shown by mutational analysis of the CD4 molecule (Peterson and Seed, 1988; Sattentau et al., 1989; Ashkenazi et al., 1990) .
(b) Synthesis of chimeric mAb M-T151 and M-T310 in transfectomas
Genomic VJ and VDJ regions of mAbs M-T151 and M-T3 10 were isolated by the PCR reaction, fused to human IC and yl constant regions, transfected into Sp2/0 cells and stable transformants isolated by G418 selection. Details are described in Weissenhorn et al. (1991) . Fig. 2 reveals that transfectants with steady state levels of K-and ylspecific transcripts corresponding in abundance to those of the original hybridoma cells could be isolated after screening about 200 transfectants for each chimeric mAb. This holds true with the exception of the transfectant shown in Fig. 2B, lanes d and j. With the K--specific V region probe, slight cross-hybridisation to an endogeneous IC message in the recipient cell line Sp2/0 was observed (Fig. 2A, lane c) . This message contains a premature stop codon and does not mediate synthesis of a secreted, truncated protein (Cabilly and Riggs, 1985) . Synthesis of murine and chimeric mAb corresponds to 15-20 pg/ml/106 cells/24 h. The isolated VJ and VDJ regions contain the authentic introns in the signal sequences of L and H chains. Expression of the chimeric genes is mediated by a tandem combination of a H chain promoter/enhancer element (Weissenhorn et al., 1991) . The result indicates that transfectomas with expression levels of chimeric mAb corresponding to those of the original hybridoma can be established with this experimental design without the need to amplify transfected genes. 
(c) Complement activation
As the aim of targeted mAb therapy is either modulation of the CD4 molecule (Lifson and Engleman, 1989) or elimination of reactive T cells, it was important to evaluate the complement activation properties of our mAbs. Compared with other human Ig subclasses, the greatest effectiveness with respect to physiological effector functions has been described for the IgGl isotype (Brtiggemann et al., 1987; Riechmann et al., 1988) . We therefore selected the human IgG 1 isotype for chimerization of the anti-CD4 mAbs. The activation of complement was assayed by determination of the ability of the mAbs to induce deposition of components of the complement cascade on the surface of CD4' PBL.
The results show that murine M-T151 (IgG,,) activates human complement weakly (Fig. 3a) , whereas murine M-T310 (IgGl) is negative with respect to this property (Fig. 3b) . The combination of these murine anti-CD4 mAbs results in a dramatic enhancement of activation of human complement (Fig. 3~) . The chimeric mAbs M-T15 1 (IgGl) and M-T3 10 (IgGl) do not display human complementactivating properties (Fig. 3d ,e) by themselves; however, a combination of these mAbs results in complement activation stronger than the activation induced by a combination of the murine mAb (Fig. 3f) . As a negative control, mAbtargeted cells have been incubated with heat-inactivated serum. Consistently, only background levels of fluorescence intensity have been observed (data not shown). Unfortunately, a lytic mAb pair was not available for our studies. Synergy with respect to complement activation for pairs of 
(d) Immunomodulation by chimeric anti-CD4 mAbs
To determine the possible role of modulation of CD4+ cells rather than elimination of these cells, the effect of anti-CD4 mAbs on whole blood cells was determined. Anti-CD4 mAb has the potential to modulate the function of CD4" cells either by delivering an ~activating signal (Rosoff et al., 1987) or by inhibiting the association of the CD4 molecule with the T cell receptor-CD3 complex or by blocking its interaction with MHC class II molecules on cooperating cells. In vivo experiments have shown that the immunosuppressive effect and the induction of tolerance by anti-CD4 mAbs does not entirely depend on cell depletion {Benjamin et Alters et al., 1990; Cobbold et al., 1990; Qin et al., 1990) . Furthermore it has been shown that Fab fragments of an anti-CD4 mAb mediate immunosuppression (Carteron et al., 1988) . Qin et al. (1987) have demonstrated an improved clearance of cells in vivo and tolerance induction, using synergistic pairs of anti-CD4 mAbs. For methods see Table I .
(e) Inhibition of MLR When lymphocytes from two genetically different individuals of a species are mixed in cell culture medium, the T cells of each indi~dual respond to the MHC antigens of the other by d~erentiation and proliferation. This process is called mixed lymphocyte reaction (MLR). Allogeneic antigens presented on accessory cells stimulate precursor cells, and the effector cells secrete IL2 and other lymphokines that cause maturation of effector T cells. Since these mechanisms are responsible for allograft rejection, it is of great interest to suppress T-cell reactivity in allograft patients. In the present study we demonstrate that each chimerit anti-CD4 mAb by itself inhibits markedly MLR. This can also be achieved by the anti-IL2Ra mAb MAK179. As shown in Table I , a dose-dependent inhibition of the MLR up to a concentration of 300 ngjml can be obtained with these three mAbs. The maximum inhibition of MLR is about 60-70 %. An increase of the mAb concentration to 30 pg/ml did not result in any further increase in inhibition.
Probably, the proliferation of lymphocytes is supported by additional signals, besides those mediated by CD4 and
IL2R.
For clinical applications it is important to accomplish a high degree of suppression of T-cell proliferation. In Table  II we show that a combination of the chimeric anti-CD4 mAbs M-T310 and M-T151 did not lead to a marked increase in MLR inhibition; however, either of the anti-CD4 mAbs (M-T310 or M-T151) in combination with the antiIL2Ra mAb MAK 179 mediates an almost 100% inhibition of MLR, using each mAb in a concentration of 100 ng/ ml. The combination of each anti-CD4 mAb and another anti-ILfRa mAb M215, which does not compete with binding of IL2 to its receptor (unpublished observations), did not show any synergistic effect, even when used at a concentration of 10 pg/ml (data not shown). In addition, even at reduced concentrations (10 ng/ml of each mAb) the combination of either one of the two anti-CD4 mAbs and the anti-IL2Ra mAb MAK 179 resulted in almost 50% inhibition of the MLR.
These data show that an inhibition of the MLR can be achieved very effectively by the combined administration of one of the two anti-CD4 mAbs and the anti-ILfRa mAb MAK 179. During treatment of autoimmune diseases and following organ transplantation, mAbs are administered in doses ranging from 20 to 50 mg per day. By using an anti-CD4/IL2Ra mAb cocktail, we assume that the same immunosuppressive effect might be obtained by a 5-10 times lower dose than when using either one alone.
(f) Conclusions (I) We were able to establish transfectomas with Igspecific mRNA steady state levels comparable to those of the original hybridoma cell lines with our cloning/ expression system. The mRNA steady state levels correlated with the secretion of reconstituted mAb into the culture supernatants.
(2) Selective T-cell-targeted therapy is an attractive alternative to non-specific immunosuppressive drugs in the treatment of graft rejections as well as autoimmune disorders. The chimerization of mAbs reduces their immunogenicity (Brtiggemann et al., 1989) for serotherapy in humans, it enhances the serum half-life and improves physiological effector functions (reviewed by Waldmann, 1991b) . (3) Chimeric mAbs M-T151 and M-T310 seem to be suitable for the therapy of autoimmune diseases. The murine mAb M-T 15 1 has been already used successfully in a limited trial (Herzog et al., 1987) . Complement activation and antigen modulation are only performed by a combination of the chimeric anti-CD4 mAb; the individual mAbs do not display these properties. Therefore, we suggest that a combination of both chimeric mAbs is more effective than the administration of a single mAb.
(4) For the treatment of graft rejections, a combination of an anti-IL2Rcr-chain mAb and an anti-CD4 mAb seems to be a very effective combination, as T-cell proliferation can be almost completely suppressed.
(5) Our study shows that combinations of mAbs are more effective than single mAbs with respect to several properties (complement activation, CD4 modulation, inhibition of MLR). Cocktails of mAbs containing anti-CD4 mAbs and/or IL2Ra mAbs and also mAbs directed to other T-cell accessory molecules should provide new tools for immunotherapy.
